alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAY-31-1998
<PERIOD-START>                             JUN-01-1997
<PERIOD-END>                               AUG-31-1997
<EXCHANGE-RATE>                                      1
<CASH>                                          70,491
<SECURITIES>                                         0
<RECEIVABLES>                                   46,401
<ALLOWANCES>                                         0
<INVENTORY>                                     39,388
<CURRENT-ASSETS>                               160,570
<PP&E>                                          32,294
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 220,095
<CURRENT-LIABILITIES>                           54,341
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             1
<OTHER-SE>                                     164,721
<TOTAL-LIABILITY-AND-EQUITY>                   220,095
<SALES>                                         51,915
<TOTAL-REVENUES>                                53,847
<CGS>                                           30,831
<TOTAL-COSTS>                                   46,985
<OTHER-EXPENSES>                                 (759)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  7,621
<INCOME-TAX>                                     2,793
<INCOME-CONTINUING>                              4,828
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,557
<EPS-PRIMARY>                                     0.39
<EPS-DILUTED>                                        0
        

</TABLE>
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 96-7378
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus WAYNE P. THOMAS, a/k/a Eugene Gregory, Defendant - Appellant. Appeal from the United States District Court for the District ofMaryland, at Baltimore. Frederic N. Smalkin, District Judge. (CR91-212-S, CA-96-2587-S) Submitted: December 9, 1997 Decided: January 6, 1998 Before ERVIN, LUTTIG, and MICHAEL, Circuit Judges. Dismissed by unpublished per curiam opinion. Wayne P. Thomas, Appellant Pro Se. Stephen S. Zimmermann, OFFICE OF THE UNITED STATES ATTORNEY, Greenbelt, Maryland, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Appellant seeks to appeal the district court's order denying his motion filed under 28 U.S.C.A. § 2255 (West 1994 & Supp. 1997). We have reviewed the record and the district court's opinion andfind no reversible error. Accordingly, we deny a certificate of appealability and dismiss the appeal on the reasoning of the district court. United States v. Thomas , Nos. CR-91-212-S; CA-96-2587-S (D. Md. Aug. 22, 1996). We dispense with oral argument because thefacts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
§ 522.1020 Gelatin. ( a ) *Specifications.* Each 100 milliliters contains 8 grams of gelatin in a 0.85 percent sodium chloride solution.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* The exact dosage to be administered must be determined after evaluating the animal's condition and will vary according to the size of the animal and the degree of shock. A suggested dosage range for small animals such as dogs is 4 to 8 cubic centimeters per pound body weight. The suggested dosage range for large animals such as sheep, calves, cows, or horses is 2 to 4 cubic centimeters per pound of body weight.
( 2 ) *Indications for use.* For use to restore circulatory volume and maintain blood pressure in animals being treated for shock.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16189, Mar. 25, 2014]
§ 315.5 Evaluation of effectiveness. ( a ) The effectiveness of a diagnostic radiopharmaceutical is assessed by evaluating its ability to provide useful clinical information related to its proposed indications for use. The method of this evaluation varies depending upon the proposed indication(s) and may use one or more of the following criteria: ( 1 ) The claim of structure delineation is established by demonstrating in a defined clinical setting the ability to locate anatomical structures and to characterize their anatomy.
( 2 ) The claim of functional, physiological, or biochemical assessment is established by demonstrating in a defined clinical setting reliable measurement of function(s) or physiological, biochemical, or molecular process(es).
( 3 ) The claim of disease or pathology detection or assessment is established by demonstrating in a defined clinical setting that the diagnostic radiopharmaceutical has sufficient accuracy in identifying or characterizing the disease or pathology.
( 4 ) The claim of diagnostic or therapeutic patient management is established by demonstrating in a defined clinical setting that the test is useful in diagnostic or therapeutic patient management.
( 5 ) For a claim that does not fall within the indication categories identified in § 315.4, the applicant or sponsor should consult FDA on how to establish the effectiveness of the diagnostic radiopharmaceutical for the claim.
( b ) The accuracy and usefulness of the diagnostic information is determined by comparison with a reliable assessment of actual clinical status. A reliable assessment of actual clinical status may be provided by a diagnostic standard or standards of demonstrated accuracy. In the absence of such diagnostic standard(s), the actual clinical status must be established in another manner, e.g., patient followup.
## F IRST 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________
No. 1D 21

- 674

_____________________________

M ARVIN K NIGHT ,
Appellant,

v.

S TATE O F F LORIDA ,
Appellee.

_____________________________

On appeal from the Circuit Court for Leon County

. Stephen S. Everett , Judge

.
September 29, 2021

P ER C URIAM

.

A FFIRMED

. The Court warns Appellant that any future filings that this Court determines to be frivolous may result in the imposition of sanctions, including a prohibition against any further pro se filings in this Court and a referral to the appropriate institution f or disciplinary procedures. See § 944.279, Fla. Stat. (2021).

R OWE , C.J., and L EWIS and W INOKUR , JJ., concur.2 _____________________________ Not final until disposition of any timely and authorized motion under Fla. R. App. P. 9.330 or 9.331

.

_____________________________

Marvin Knight, pro se

, Appellant.

Ashley Moody, Attorney General, and Bryan Jordan, Assistant Attorney General, Tallahassee

, for Appellee.
Exhibit 32 (b)
 CERTIFICATION PURSUANT TO 18 U.S.CSECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  (1)
    
    The Form 10-Q fully complies with the requirements of Section 13 (a) or
(15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78(d)); and(2)
    
    The information contained in the Form 10-Q fairly presents in all
material respects, the financial condition and results of operations of the
Partnership.
 Date:
8-21-08
 /s/
    
    GARY S. JONES

Gary S. JonesPresident
 A signed original of this written statement required by Section 906 has been provided to Northland
Cable Properties Seven Limited Partnership and will be retained by Northland Cable Properties Seven
Limited Partnership and furnished to the Securities and Exchange Commission or its staff upon
request.
**Exhibit32**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACTOF 2002**

The certifications set forth below are hereby submitted to the Securitiesand Exchange Commission pursuant to, and solely for the purpose of complyingwith, Section 1350 of Chapter 63 of Title 18 of the United States Code inconnection with the filing on the date hereof with the Securities and ExchangeCommission of the Quarterly Report on Form 10-Q of the Company for thequarter ended June 30, 2007.

Eachof the undersigned hereby certifies in his capacity as an officer of CitizensBancshares Corporation and subsidiaries (the “Company”) that, to his knowledgeon the date of this certification, the Quarterly Report of the Company on Form10-Q for the period ended June 30, 2007 fully complies with the requirements ofSection 13(a) of the Securities Exchange Act of 1934 and that the informationcontained in such report fairly presents, in all material respects, thefinancial condition of the Company at the end of such period and the results ofoperations of the Company for such period.
| Date:   August 14, 2007 | By: /s/ James E. Young                |   |
|----------------------------------------|---------------------------------------|--------|
|                                   | James E. Young                        |
|                                   | President and Chief Executive Officer |
|                                   |                                  |
|                                   |                                  |
| Date:   August 14, 2007 | By: /s/ Cynthia N. Day                |   |
|                                   | Cynthia N. Day                        |
|                                   | Senior Executive Vice President and   |
|                                   | Chief Operating Officer               |
|                                   |                                  |
|                                   |                                  |
| Date:   August 14, 2007 | By: /s/ Samuel J. Cox                 |   |
|                                   | Samuel J. Cox                         |
|                                   | Executive Vice President and          |
|                                   | Chief Financial Officer               |

 

1

----
38772.

#### LOGAN v. THE STATE.

Frankum, Judge.

Jack Clyde Logan was convicted of the offense of burglary. He filed a motion for a new trial on general grounds only. The trial court overruled the motion, and the defendant assigns this ruling as error.

The evidence adduced on the trial of this case was sufficient for the jury to find, beyond a reasonable doubt, that a burglary was committed as charged in the indictment; that at the time the house was broken open and entered, an Amoco credit card, No. 4651843007, the property of Comer F. Hampton, was in the house; that this particular credit card, $241.24 in money, and several checks were stolen and taken from the house when the burglary was committed; that shortly thereafter the defendant had possession of said credit card and used it on several occasions in making purchases of personal property on credit; that on each occasion when the credit card was thus used by the defendant, he signed the name of Comer F. Hampton on an invoice showing the items of property purchased, all without the knowledge or consent of Comer F. Hampton, and that the defendant’s possession of the credit card shortly after the burglary was committed was not satisfactorily explained.

Facts shown by the evidence were not only consistent with the hypothesis of guilt, but were sufficient to exclude every other *474reasonable hypothesis save that of the guilt of the defendant. *Harrison v. State,*74 Ga. 801.

Decided April *5,*1961.

*Jean E. Johnson, Sr.,*for plaintiff in error.

*Paul Webb, Solicitor-General, Thomas R. Luck, Jr., Eugene L. Tiller,*contra.

*Judgment affirmed.*

*Townsend, P. J., Carlisle and Jordan, JJ., concur.*
**Exhibit 31.2**

 

 

CERTIFICATIONS

 

I, Craig Fraser, certify that:

 

1.     I have reviewed this Amendment No. 1 on Form 10-K/A of Windtree Therapeutics, Inc. for the year ended December 31, 2017; and

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

 

 

| Date: April 30, 2018 |   | /s/ Craig Fraser                      |   |
|----------------------|--------|---------------------------------------|--------|
|                 |   | Craig Fraser                          |   |
|                 |   | President and Chief Executive Officer |   |

 

----

 

**Exhibit 31.2**

 

CERTIFICATIONS

 

I, John Tattory, certify that:

 

1.     I have reviewed this Amendment No. 1 on Form 10-K/A of Windtree Therapeutics, Inc.; and

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

 

 

| Date: April 30, 2018 |   | /s/ John Tattory                                    |   |
|----------------------|--------|-----------------------------------------------------|--------|
|                 |   | John Tattory                                        |   |
|                 |   | Senior Vice President and 

Chief Financial Officer |   |
§ 350.50 Labeling of antiperspirant drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as an “antiperspirant.”
( b ) *Indications.* The labeling of the product states, under the heading “Uses,” the phrase listed in paragraph (b)(1) of this section and may contain any additional phrases listed in paragraphs (b)(2) through (b)(5) of this section, as appropriate. Other truthful and nonmisleading statements, describing only the uses that have been established and listed in paragraphs (b)(1) through (b)(5) of this section, may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act. ( 1 ) For any product, the labeling states [select one of the following: “decreases,” “lessens,” or “reduces”] “underarm” [select one of the following: “dampness,” “perspiration,” “sweat,” “sweating,” or “wetness”].
( 2 ) The labeling may state “also [select one of the following: ‘decreases,’ ‘lessens,’ or ‘reduces’] underarm [select one of the following: ‘dampness,’ ‘perspiration,’ ‘sweat,’ ‘sweating,’ or ‘wetness’] due to stress”.
( 3 ) For products that demonstrate standard effectiveness (20 percent sweat reduction) over a 24-hour period, the labeling may state [select one of the following: “all day protection,” “lasts all day,” “lasts 24 hours,” or “24 hour protection”].
( 4 ) For products that demonstrate extra effectiveness (30 percent sweat reduction), the labeling may state “extra effective”.
( 5 ) Products that demonstrate extra effectiveness (30 percent sweat reduction) sustained over a 24-hour period may state the claims in paragraphs (b)(3) and (b)(4) of this section either individually or combined, e.g., “24 hour extra effective protection”, “all day extra effective protection,” “extra effective protection lasts 24 hours,” or “extra effective protection lasts all day”.
( c ) *Warnings.* The labeling of the product contains the following statements under the heading “Warnings”: ( 1 ) “Do not use on broken skin”.
( 2 ) “Stop use if rash or irritation occurs”.
( 3 ) “Ask a doctor before use if you have kidney disease”.
( 4 ) *For products in an aerosolized dosage form.* ( i ) “When using this product [bullet][1] keep away from face and mouth to avoid breathing it”.
( ii ) The warning required by § 369.21 of this chapter for drugs in dispensers pressurized by gaseous propellants.
( d ) *Directions.* The labeling of the product contains the following statement under the heading “Directions”: “apply to underarms only”.
Effective Date Note
Effective Date Note: At 69 FR 61149, Oct. 15, 2004, the limitation of the enhanced duration claim to 24 hours (21 CFR 350.50 (b)(3) and (b) (5)) was stayed until further notice.
Footnotes -
350.50
[1] See § 201.66(b)(4) of this chapter for definition of bullet.
4

5 10

9

7

3 8

 serve small portions 

 It’s not necessary to get rid of all sweets and desserts.

Show kids that a small amount of treats can go a long 

way. Use smaller bowls and plates for these foods. Have 

them share a candy bar or split a large cupcake.

 sip smarter Soda and other sweet drinks contain

a lot of sugar and are high in calories. 

Offer water, 100% juice, or fat-free milk 

when kids are thirsty.

 use the check-out lane 

 that does not display candy

 Most grocery stores will have a candy-free check-out 

lane to help moms out. Waiting in a store line makes it easy 

for children to ask for the candy that is right in front of their 

faces to tempt them. 

 choose not to offer sweets as rewards 

 By offering food as a reward for good behavior, 

 children learn to think that some foods are better 

than other foods. Reward your child with kind words and 

comforting hugs, or give them non-food items, like stickers, 

to make them feel special.

 make fruit the everyday dessert Serve baked apples, pears, or 

 enjoy a fruit salad. Or, serve 

yummy frozen juice bars (100% juice)

instead of high-calorie desserts. 

 

6

2

1

cut back on your kid’s

sweet treats 

10 tips to decrease added sugars

Limit the amount of foods and beverages with added sugars your kids eat and drink. If you 

don’t buy them, your kids won’t get them very often. Sweet treats and sugary drinks have a lot of calories but few 

nutrients. Most added sugars come from sodas, sports drinks, energy drinks, juice drinks, cakes, cookies, ice 

cream, candy, and other desserts.

 DG TipSheet No. 13 

 June 2011

Center for Nutrition USDA is an equal opportunity 

Policy and Promotion Go to www.ChooseMyPlate.gov for more information. provider and employer.

10

tips

Nutrition 

Education Series

 make food fun

 Sugary foods that are marketed to kids are 

 advertised as “fun foods.” Make nutritious foods fun 

by preparing them with your child’s help and being creative 

together. Create a smiley face with sliced bananas and 

raisins. Cut fruit into fun and easy shapes with cookie cutters.

 encourage kids to invent new snacks

 Make your own snack mixes from 

 dry whole-grain cereal, dried fruit, 

and unsalted nuts or seeds. Provide 

the ingredients and allow kids to choose 

what they want in their “new” snack.

play detective in the cereal aisle 

Show kids how to find the amount of total sugars 

in various cereals. Challenge them to compare 

cereals they like and select the one with the lowest 

amount of sugar. 

 make treats “treats,” 

 not everyday foods

 Treats are great once in a while. Just don’t make 

treat foods an everyday thing. Limit sweet treats to special 

occasions. 

 if kids don’t eat their meal, they 

 don’t need sweet “extras”

 Keep in mind that candy or cookies should not 

replace foods that are not eaten at meal time.
Attachment 11

The relief provided by Exemption No. 10690H is limited to the air carriers listed below: 

Airlines for America 

Alaska Airlines 

American Airlines 

Atlas Air, Inc. 

Hawaiian Airlines, Inc. 

JetBlue Airways Corp. 

Southwest Airlines Co. 

United Airlines, Inc 

Air Canada (Associate Member) 

National Air Carrier Association 

Air Transport International 

Allegiant Air 

Atlas Air, Inc. 

Eastern Airlines 

Everts Air Cargo 

Kalitta Air 

Lyndon Air Cargo 

Miami Air International 

National Airlines 

National Air Cargo 

Northern Air Cargo 

Omni Air International 

Southern Air 

Spirit Airlines 

Sun Country Airlines 

USA Jet Airlines 

Western Global 

Regional Airline Association 

Air Wisconsin Airlines Corp. 

Cape Air 

CommutAir 

Compass Airlines 

Empire Air 

Endeavor Airlines 

Envoy 

ExpressJet Airlines 

GoJet Airlines 

Grand Canyon Airlines/Scenic 

Great Lakes Aviation 

 

1

 Attachment amended May 26, 2017. 
Hawaii Island Air 

Horizon Air 

Jazz Air 

Mesa Airlines 

New England Airlines 

Piedmont Airlines 

PSA Airways 

RAVN Alaska 

Republic Airlines 

Seaborne Airlines 

Shuttle America 

Silver Airways 

SkyWest Airlines 

Surf Air 

Trans States Airlines 

Additional Air Carriers2

Delta Air Lines, Inc. 

Peninsula Airways 

Virgin America, Inc. 

Vision Airlines, Inc. 

 

2

 Additional air carriers petitioned for exemption through the following FAA Docket Numbers: Delta Air Lines, 

FAA-2013-0034; Peninsula Airways, FAA-2017-0196; Virgin America, FAA-2013-0034; Vision Airlines, FAA2016-8158
**UN PUBLISHED** 

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

**No. 14** 

**- 14**  **4 0** 

ADAM L. PERRY ,

P laintiff

- Appell ant ,

v.

ENTERTAINMENT ONE (KOCH RECORDS)
,

Defendan t

- Appell ee ,

and

EMI MUSIC, INCORPORATED; LENCH MOB RECORDS; WILLIAM CALHOUN
,

Defendants

.

Appeal from the United States District Court for the Eastern District of North Carolina , at Elizabeth City

. W. Earl Britt

, Senior District Judge. ( 2 : 1 3

- c v

- 00 0 22

- BR )

Submitted : September 25, 2014 Decided: September 29, 2014

Before WILKINSON and AGEE , Circuit Judges , and DAVIS, Senior Circuit Judge

.

Affirm ed by un published per curiam opinion

.

Adam L. Perry , Appellant Pro Se. Daniel J. Aaron, DANIEL J. AARON, PC, New York, New York; Ernest Bradley Evans, WARD & SMITH, PA , Greenville, North Carolina , for Appellee.

Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM:

Adam L. Perry appeals the district court ’ s order

granting summary judgment to Defendants on his claim that they

misappropriated his identity . We have reviewed the record and

find no reversible error. Accordingly, we affirm for the

reasons stated by the district court. Perry v. Entm’t One , No.

2:13

- cv

- 00022

- BR (E.D.N.C. Apr. 23, 2014)

. We grant Perry leave

t o proceed in forma pauperis. We dispense with oral argument

because the facts and legal contentions are adequately presented

in the materials before th is court and argument would not aid

the decisional process.

AFFIRMED